Gubra to get up to 240 million euros in new Boehringer deal

German pharma major Boehringer Ingelheim and Danish biotech Gubra have announced a second collaboration and license agreement for the development of new poly-agonist peptides to treat obesity.

This second joint research and development program involving the privately-held companies builds on an ongoing collaboration in the obesity field which was launched in 2017 and which has already achieved certain milestones set at the outset.

As part of the new deal, Gubra could receive up to 240 million euros ($267 million) in upfront and success-based development and commercialization milestones plus staggered up to double-digit royalties on worldwide net sales.